Tim Opler News Today

An ETF that tracks the biotech sector closed above $100 for the first time in just over two years on Tuesday.

Bets on interest-rate cuts plus a surge in pharma deals mean the worst is likely over for the biotech sector

As investors begin to see light at the end of the tunnel, their risk appetite, which had vanished amid recession risks and volatility, is coming back, creating chances of major investments in high-risk...

BioPharma

44pc users experience nausea; Obesity market could be worth $100bn by 2030

By Maggie Fick LONDON (Reuters) - Weight-loss drug Wegovy helped Rebecca Vogt achieve a major goal - shedding the weight she had not managed to drop s...

Weight-loss drug Wegovy helped Rebecca Vogt achieve a major goal - shedding the weight she had not managed to drop since giving birth. "The nausea is just so awful with this medication," said Vogt, who had endured daily sickness for months. After stopping taking the weekly injection, Vogt, a 48-year-old customer service representative in Buffalo, New York, said she regained the 27 pounds (12.2 kilograms) she had lost.

Torreya Partners is an independent M&A and private capital advisory firm serving the global life sciences industry.

This year, biotech is more like a biowreck. A burgeoning sector last year, biotech has taken this year's market tumble harder than even the most...